Table 1 Details of clinical characteristics of the patients with rare ARHGAP10 variants.
From: ARHGAP10, which encodes Rho GTPase-activating protein 10, is a novel gene for schizophrenia risk
| Â | Case #1 | Case #2 | Case #3 | Case #4 | Case #5 | Case #6 | Case #7 |
|---|---|---|---|---|---|---|---|
Genotype | Exonic deletion in ARHGAP10 | Exonic deletion in ARHGAP10 | Exonic deletion in ARHGAP10 | Exonic deletion in ARHGAP10 | Exonic deletion and p.S490P in ARHGAP10 | Exonic duplication in ARHGAP10 | Exonic deletion in ARHGAP10 |
Diagnosis | SCZ | SCZ | SCZ | SCZ | SCZ | SCZ | SCZ |
Age/sex | 20/M | 43/M | 35/M | 42/M | 62/M | 46/M | 48/M |
Family history | None | ID | None | SCZ | SCZ | None | None |
History of development | Normal | NA | Normal | Normal | Poor academic performance and social skills | NA | Normal |
Age of onset | 18 | 24 | 32 | 37 | 19 | 17 | 20 |
Main symptoms | Persecutory delusion, social withdrawal | Delusion, hallucination | Disorganized speech and behavior, thought broadcasting, agitation, depressive symptoms | Disorganized speech and behavior, persecutory delusion, auditory hallucination, negative symptoms, cognitive impairment | Delusion, visual hallucination, violent and aggressive behavior, negative symptoms, cognitive impairment | Persecutory delusion, auditory hallucination | Delusion of reference and observation, interpersonal tension |
Length of hospitalization | None | 19 years | <1 year | 4 years | 8 years | >20 years | None |
Doses of antipsychotics (chlorpromazine equivalent) | NA | 2700 mg | 480 mg | 1300 mg | 410 mg | 1050 mg | 1700 mg |
Response to treatment | NA | Poor | Poor | Poor | Poor | Poor | Poor |
Comorbidity of physical illnesses | Febrile seizures, benign tumor | None | None | Atrial septal defect | Hypertension, diabetes mellitus, rheumatoid arthritis, psoriasis | Anemia | Hyperlipemia |
